This is a technical analysis of VKTX stock, also called Viking Therapeutics. It is highlighted that the biotech sector is at a turn around point and the company is specializes in the development of novel therapies for metabolic and endocrine disorders that addresses conditions like obesity, this could means good fat loss stuff ahead. Two drugs VK2735 and VK2809. The company recently got positive FDA feedback about their pipeline. The 50-day moving average indicates that there is an upward trend, but VKTX is in a consolidation phase having found resistance at 35.50.The analysis suggests a buy at above 35.50 and a fail bound at 31.40. The Motley Fool and other analysts predict a target price of $70. If all goes well this stock could either turn into a Major Healthcare player or they will be acquired, either way both cases leads to good news for the shareholders.